Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Servier and miRagen Therapeutics have announced the selection of a third target under the agreement aimed at advancing the research and commercialization of microRNA-based drug candidates against cardiovascular diseases.
Subscribe to our email newsletter
Selection of the third cardiovascular target by Servier marks the first milestone for miRagen under the collaboration.
Servier chief executive officer Dr. Jean-Philippe Seta said, "Micro-RNA is now the gateway to acting at the deepest level of gene expression regulation, with exciting prospects of major developments in the treatment of cardiovascular disease."
In October 2011, miRagen and Servier entered into a strategic alliance to advance microRNA-based therapies in cardiovascular disease.
The alliance that initially included miR-208 and miR-15/195 gave Servier a right to add an additional target.
miRagen Therapeutics president and chief executive officer William Marshall said, "We remain deeply committed to the discovery and advancement of microRNA-based therapeutics, and we anticipate that our partnership with Servier will yield life-changing treatment options for patients in need."